ESMO 2021, News
There was no improvement in overall survival with bevacizumab.
News
Study shows reductions in intraocular pressures and antiglaucoma medication use.
ESMO 2021, News
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
News
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Drugs in the Pipeline
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
ESMO 2021, News
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.